{"id":"p2y12-antagonist-monotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (major and minor)"},{"rate":null,"effect":"Dyspnea"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Gastrointestinal bleeding"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"P2Y12 is a G-protein coupled receptor on platelets that mediates ADP-induced platelet activation and aggregation. By antagonizing this receptor, P2Y12 inhibitors reduce platelet clumping and blood clot formation. This antiplatelet effect is used to prevent thrombotic cardiovascular events in patients at risk.","oneSentence":"P2Y12 antagonists block the P2Y12 adenosine diphosphate receptor on platelet surfaces, preventing platelet aggregation and thrombus formation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:59:30.800Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (ACS) including ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI)"},{"name":"Secondary prevention of atherothrombotic events in patients with prior myocardial infarction or stroke"},{"name":"Peripheral arterial disease"}]},"trialDetails":[{"nctId":"NCT06763744","phase":"PHASE4","title":"Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2025-06-01","conditions":"Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), High Bleeding Risk","enrollment":3000},{"nctId":"NCT03447379","phase":"NA","title":"Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent","status":"COMPLETED","sponsor":"Gangnam Severance Hospital","startDate":"2017-12-15","conditions":"Coronary Artery Disease","enrollment":1452},{"nctId":"NCT05307718","phase":"","title":"Pharmacogenomics in Prediction of Cardiovascular Drugs Adverse Reaction","status":"UNKNOWN","sponsor":"Clinical Hospital Centre Zagreb","startDate":"2020-12-15","conditions":"Pharmacogenetics, Drug-Related Side Effects and Adverse Reactions, Cardiovascular Drugs","enrollment":1200},{"nctId":"NCT02079194","phase":"NA","title":"Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2014-03-18","conditions":"Coronary Artery Disease","enrollment":3000},{"nctId":"NCT02227368","phase":"PHASE2","title":"Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2014-10-20","conditions":"Peripheral Artery Disease (PAD)","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"P2Y12 antagonist monotherapy","genericName":"P2Y12 antagonist monotherapy","companyName":"Samsung Medical Center","companyId":"samsung-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"P2Y12 antagonists block the P2Y12 adenosine diphosphate receptor on platelets to inhibit platelet aggregation and reduce thrombotic events. Used for Acute coronary syndrome, Percutaneous coronary intervention, Stroke prevention in patients with acute ischemic stroke or transient ischemic attack.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}